G Medical Innovations Holdings Limited announced that it has successfully completed the necessary clinical trials required to obtain National Medical Products Administration (NMPA) (formerly China Food and Drug Administration or CFDA) approval for the use of its Prizma device in the People's Republic of China. G Medical has completed the additional trials with 208 patients with three of its partner hospitals, the Guangzhou Women and Children's Medical Centre, the Zhujiang Hospital of Southern Medical University and the Sixth Affiliated Hospital of Sun Yat-sen University. As previously announced, the trials included measurements for electrocardiography (ECG), blood-oxygen saturation (SPO2) and body temperature using the Prizma device benchmarked against the relevant `gold standard' hospital diagnostic equipment. The Company is currently interpreting the large amount of statistical data generated and a dossier of results will be finalised for lodgement with the NMPA. G Medical expects to lodge the required information with the NMPA by the end of April 2020, and is confident that it will receive NMPA clearance for its Prizma medical device. NMPA approval for the Prizma device will allow for the commencement of G Medical's commercial sales and services activities within the Chinese market. NMPA approval for the manufacture of the Company's medical devices has already been granted for its Guangzhou production facility, leaving it well positioned to capitalise once NMPA approval for the Prizma device is granted. Further, on receipt, the NMPA approval for the Prizma device will allow G Medical to accelerate existing distribution and services arrangements with its China partners being; Beijing SilverLake Investment Co. Ltd. ("SilverLake") and Shandong Boletong Information S&T Co. Ltd. ("Boletong"), underpinning multiple potential revenue streams (in accordance with requirements to the respective agreements as previously announced). The Company is continuing the NMPA regulatory approval process for its GMP `Patch' (VSMS) and will provide further updates as developments are progressed.